Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro

Journal of Pharmacology and Experimental Therapeutics

Volumn 319, Issue 2, 2006, Pages 561-569

  Madras, Bertha K ^a   Xie, Zhihua ^a   Lin, Zhicheng ^a   Jassen, Amy ^a   Panas, Helen ^a   Lynch, Laurie ^a   Johnson, Ryan ^a   Livni, Eli ^b   Spencer, Thomas J ^b   Bonab, Ali A ^b   Miller, Gregory M ^a   Fischman, Alan J ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; BENZATROPINE; CELL RECEPTOR; DOPAMINE TRANSPORTER; METHYLPHENIDATE; MODAFINIL; NORADRENALIN TRANSPORTER; PHENETHYLAMINE; SEROTONIN TRANSPORTER; TRACE AMINE RECEPTOR 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG PROTEIN BINDING; FEMALE; HUMAN; HUMAN CELL; HYPOTHALAMUS; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR UPREGULATION; RHESUS MONKEY; WAKEFULNESS;

ANIMALS; BENZHYDRYL COMPOUNDS; BRAIN; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MACACA MULATTA; MALE; NOREPINEPHRINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PHENETHYLAMINES; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, G-PROTEIN-COUPLED; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; WAKEFULNESS;

EID: 33751186720     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.106583     Document Type: Article

References (56)

1. Akaoka H, Roussel B, Lin JS, Chouvet G, and Jouvet M (1991) Effect of modafinil and amphetamine on the rat catecholaminergic neuron activity. Neurosci Lett 123:20-22.
2. Banerjee D, Vitiello MV, and Grunstein RR (2004) Pharmacotherapy for excessive daytime sleepiness. Sleep Med Rev 8:339-354.
3. Bastuji H and Jouvet M (1988) Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Prog Neuropsychopharmacol Biol Psychiatry 12:695-700.
4. Biederman J, Swanson JM, Wigal SB, Kratochvil CJ, Boellner SW, Earl CQ, Jiang J, and Greenhill L (2005) Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics 116:e777-e784.
5. Borowsky B, Adham N, Jones KA, Raddatz R, Artymyshyn R, Ogozalek KL, Durkin MM, Lakhlani PP, Bonini JA, Pathirana S, et al. (2001) Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc Natl Acad Sci USA 98:8966-8971.
6. Boutrel B and Koob GF (2004) What keeps us awake: the neuropharmacology of stimulants and wakefulness-promoting medications. Sleep 27:1181-1194.
7. Bunzow JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI, Darland T, Suchland KL, Pasumamula S, Kennedy JL, et al. (2001) Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol 60:1181-1188.
8. Cameron DL and Williams JT (1994) Cocaine inhibits GABA release in the VTA through endogenous 5-HT. J Neurosci 14:6763-6767.
9. Dackis C and O'Brien C (2003) Glutamatergic agents for cocaine dependence. Ann NY Acad Sci 1003:328-345.
10. Deroche-Gamonet V, Darnaudery M, Bruins-Slot L, Piat F, Le Moal M, and Piazza PV (2002) Study of the addictive potential of modafinil in naive and cocaine-experienced rats. Psychopharmacology (Berl) 161:387-395.
11. Duteil J, Rambert FA, Pessonnier J, Hermant JF, Gombert R, and Assous E (1990) Central alpha 1-adrenergic stimulation in relation to the behaviour stimulating effect of modafinil; studies with experimental animals. Eur J Pharmacol 180:49-58.
12. Engber TM, Koury EJ, Dennis SA, Miller MS, Contreras PC, and Bhat RV (1998) Differential patterns of regional c-Fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil. Neurosci Lett 241:95-98.
13. Engele J (1998) Spatial and temporal growth factor influences on developing midbrain dopaminergic neurons. J Neurosci Res 53:405-414.
14. Ferraro L, Antonelli T, O'Connor WT, Tanganelli S, Rambert FA, and Fuxe K (1997a) Modafinil: an antinarcoleptic drug with a different neurochemical profile to damphetamine and dopamine uptake blockers. Biol Psychiatry 42:1181-1183.
15. Ferraro L, Antonelli T, O'Connor WT, Tanganelli S, Rambert F, and Fuxe K (1997b) The antinarcoleptic drug modafinil increases glutamate release in thalamic areas and hippocampus. Neuroreport 8:2883-2887.
16. A receptor blockade. Neuropsychopharmacology 20:346-356.
17. 127I] altropane: a highly selective ligand for PET imaging of dopamine transporter sites. Synapse 39:332-342.
18. 3H]MeNER to norepinephrine transporters. Synapse 56:100-104.
19. Gold LH and Balster RL (1996) Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology (Berl) 126:286-292.
20. Goulet M, Miller GM, Bendor J, Liu S, Meltzer PC, and Madras BK (2001) Nonamines, drugs without an amine nitrogen, potently block serotonin transport: novel antidepressant candidates? Synapse 42:129-140.
21. 11C]-CFT and PET in a primate model of parkinsonism. Neuroreport 3:265-268.
22. Hermant JF, Rambert FA, and Duteil J (1991) Awakening properties of modafinil: effect on nocturnal activity in monkeys (Macaca mulatta) after acute and repeated administration. Psychopharmacology (Berl) 103:28-32.
23. Jenner P, Zeng BY, Smith LA, Pearce RK, Tel B, Chancharme L, and Moachon G (2000) Antiparkinsonian and neuroprotective effects of modafinil in the MPTP-treated common marmoset. Exp Brain Res 133:178-188.
24. Kaufman MJ and Madras BK (1991) Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum. Synapse 9:43-49.
25. Lafon L (1979) inventor, Maison Alfort France, assignee. Acetamide derivates. U.S. patent 4,177,290.
26. Lin JS, Hou Y, and Jouvet M (1996) Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci USA 93:14128-14133.
27. 3H]cocaine binding sites in caudate-putamen. J Pharmacol Exp Ther 251:131-141.
28. Madras BK, Fahey MA, Goulet M, Bendor J, Lin Z, Goodrich C, Meltzer PC, Livni E, Bonab AA, and Fischman AJ (2006) Dopamine transporter (DAT) inhibitors alleviate specific parkisonian deficits in monkeys: association with DAT occupancy in vivo. J Pharmacol Exp Ther 319:570-585.
29. Madras BK, Meltzer PC, Babich JW, Bonab AA, and Fischman AJ (2001) Occupancy of the dopamine transporter by a transport inhibitor, as measured by PET imaging, is predictive of therapeutic efficacy for parkinsonism. J Nucl Med 42:210.
30. Madras BK, Meltzer PC, Liang AY, Elmaleh DR, Babich J, and Fischman AJ (1998) Altropane, a SPECT or PET imaging probe for dopamine neurons: I. Dopamine transporter binding in primate brain. Synapse 29:93-104.
31. Mignot E, Nishino S, Guilleminault C, and Dement WC (1994) Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 17:436-437.
32. Miller GM, Verrico CD, Jassen A, Konar M, Yang H, Panas H, Bahn M, Johnson R, and Madras BK (2005) Primate trace amine receptor 1 modulation by the dopamine transporter. J Pharmacol Exp Ther 313:983-994.
33. Miller GM, Yatin SM, De La Garza R, Goulet M, and Madras BK (2001) Cloning of dopamine, norepinephrine and serotonin transporters from monkey brain: relevance to cocaine sensitivity. Mol Brain Res 87:124-143.
34. Morris ED, Babich JW, Alpert NM, Bonab AA, Livni E, Weise S, Hsu H, Christian BT, Madras BK, and Fischman AJ (1996) Quantification of dopamine transporter density in monkeys by dynamic PET imaging of multiple injections of 11C-CFT. Synapse 24:262-272.
35. Morrow GR, Shelke AR, Roscoe JA, Hickok JT, and Mustian K (2005) Management of cancer-related fatigue. Cancer Investig 23:229-239.
36. Price CS and Taylor FB (2005) A retrospective chart review of the effects of modafinil on depression as monotherapy and as adjunctive therapy. Depress Anxiety 21:149-153.
37. Reid MS, Hsu K Jr, and Berger SP (1997) Cocaine and amphetamine preferentially stimulate glutamate release in the limbic system: studies on the involvement of dopamine. Synapse 27:95-105.
38. Reissig JE and Rybarczyk AM (2005) Pharmacologic treatment of opioid-induced sedation in chronic pain. Ann Pharmacother 39:727-731.
39. Saka E, Goodrich C, Harlan P, Madras BK, and Graybiel AM (2004) Repetitive behaviors in monkeys are linked to specific striatal activation patterns. J Neurosci 24:7557-7565.
40. 11C]MeNER. Nucl Med Biol 30:707-714.
41. Schou M, Halldin C, Sovago J, Pike VW, Hall H, Gulyas B, Mozley PD, Dobson D, Shchukin E, Innis RB, et al. (2004) PET evaluation of novel radiofluorinated reboxetine analogs as norepinephrine transporter probes in the monkey brain. Synapse 53:57-67.
42. Schwartz JR, Feldman NT, and Bogan RK (2005) Dose effects of modafinil in sustaining wakefulness in narcolepsy patients with residual evening sleepiness. J Neuropsychiatry Clin Neurosci 17:405-412.
43. Serrano C and Garcia-Borreguero D (2004) Fluctuations in cognition and alertness in Parkinson's disease and dementia. Neurology 63:S31-S34.
44. Simon P, Hemet C, Ramassamy C, and Costentin J (1995) Non-amphetaminic mechanism of stimulant locomotor effect of modafinil in mice. Eur Neuropsychopharmacol 5:509-514.
45. Sofuoglu M and Kosten TR (2006) Emerging pharmacological strategies in the fight against cocaine addiction. Expert Opin Emerg Drugs 11:91-98.
46. Sotnikova TD, Budygin EA, Jones SR, Dykstra LA, Caron MG, and Gainetdinov RR (2004) Dopamine transporter-dependent and -independent actions of trace amine beta-phenylethylamine. J Neurochem 91:362-373.
47. Spencer TJ, Biederman J, Ciccone PE, Madras BK, Dougherty DD, Bonab AA, Livni E, Parasrampuria DA, and Fischman AJ (2006) PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am J Psychiatry 163:387-395.
48. Stoops WW, Lile JA, Fillmore MT, Glaser PE, and Rush CR (2005) Reinforcing effects of modafinil: influence of dose and behavioral demands following drug administration. Psychopharmacology (Berl) 182:186-193.
49. van Vliet SA, Jongsma MJ, Vanwersch RA, Olivier B, and Philippens IH (2006) Behavioral effects of modafinil in marmoset monkeys. Psychopharmacology (Berl) 185:433-440.
50. Verrico C, Miller GM, and Madras BK (2005) MDMA (Ecstasy) and human dopamine, norepinephrine and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology (Berl), in press.
51. Vocci F and Ling W (2005) Medications development: successes and challenges. Pharmacol Ther 108:94-108.
52. Wisor JP and Eriksson KS (2005) Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil. Neuroscience 132:1027-1034.
53. Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, and Edgar DM (2001) Dopaminergic role in stimulant-induced wakefulness. J Neurosci 21:1787-1794.
54. Wong YN, King SP, Simcoe D, Gorman S, Laughton W, McCormick GC, and Grebow P (1999) Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects. J Clin Pharmacol 39:281-288.
55. Xie Z, Bhushan RG, Daniels DJ, and Portoghese PS (2005) Interaction of bivalent ligand KDN21 with heterodimeric δ-κ opioid receptors in human embryonic kidney 293 cells. Mol Pharmacol 68:1079-1086.
56. Yatin SM, Yatin M, Varadarajan S, Ain KB, and Butterfield DA (2001) Role of spermine in amyloid beta-peptide-associated free radical-induced neurotoxicity. J Neurosci Res 63:395-401.